UBS Financial Downgrades MannKind

Analyst Annabel Samimy believes the pharmaceutical company may not be able to file its new drug application for Technosphere Insulin until second half 2008

UBS Financial downgrades pharmaceutical company MannKind Corp. (MNKD ) to reduce from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.